Neurophysiological Correlates of Exposition Therapy in Spider Phobia

Status Recruiting

Clinical Trial Summary

This study aims to investigate the neurophysiological correlates of spider phobia and its treatment with CBT based Exposure Therapy. This is the first study to investigate the neurophysiological correlates of Exposure Therapy in situ by means of functional Near-Infrared Spectroscopy (fNIRS).

30 spider phobic patients will be assessed and randomly allocated to 5 sessions of exposure therapy or waiting-list. Further, 30 non-phobic control subjects will be assessed (primary assessment only).

During Exposure Therapy, changes in blood oxygenation will be measured with fNIRS in areas of the Cognitive Control Network. Regions of interest are the bilateral dorsolateral prefrontal cortex (DLPFC), bilateral inferior frontal gyrus (IFG) and somatosensory association cortex (SAC). Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained. After the treatment or waiting-list phase, treatment conditions are switched: The waiting list will be treated and the treated subject will wait for approximately 6 weeks.

Before treatment (primary assessment), after treatment (secondary assessment) and after study completion (final assessment), additional combined NIRS EEG measurements are done. On a peripheral physiological level heart rate and EMG of the facial corrugator supercilii are measured. During these measurements subjects are asked to watch 10s lasting video clips showing spiders (experimental condition) or pets (dogs and cats). On a psychometric level, spider phobia will be assessed by questionnaires (SPQ, FSQ, SBQ) and behavioral assessments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Phobic Disorders

Clinical Trial Details

NCT number	NCT03653923
Study type	Interventional
Source	University Hospital Tuebingen
Contact	David Rosenbaum, Dipl.-Psych.
Phone	07071-29 83609
Email	david.rosenbaum@med.uni-tuebingen.de
Status	Recruiting
Phase	N/A
Start date	October 2018
Completion date	January 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01963806` - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder	N/A
Completed	`NCT00121069` - Study of Escitalopram in the Treatment of Specific Phobia	Phase 2/Phase 3
Completed	`NCT00184106` - RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo	Phase 4
Completed	`NCT00051220` - Treatment for Specific Phobias in Children	Phase 1/Phase 2
Completed	`NCT02310152` - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)	N/A
Completed	`NCT02387047` - Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly	N/A
Completed	`NCT00000370` - Treatment of Social Phobia	N/A
Completed	`NCT03012035` - The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants	N/A
Completed	`NCT02007694` - Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants	Phase 2/Phase 3
Active, not recruiting	`NCT03188575` - Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT	N/A
Completed	`NCT02432703` - A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder	Phase 2
Terminated	`NCT01574014` - Glucocorticoid Treatment for Social Phobia	Phase 2
Completed	`NCT00734422` - Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants	Phase 2/Phase 3
Not yet recruiting	`NCT02336802` - Threat-Avoidance Learning in Anxiety Patients	N/A
Completed	`NCT01361074` - In Vivo Versus Augmented Reality Exposure for Small Animal Phobia	N/A
Completed	`NCT00104195` - A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions	Phase 1
Completed	`NCT00035412` - St. John's Wort Versus Placebo in Social Phobia	Phase 2
Completed	`NCT00128401` - Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia	Phase 2
Recruiting	`NCT02020824` - Virtual Reality and Concept of Control in the Treatment of Acrophobia	N/A
Terminated	`NCT01623583` - Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.